Stéphane Bancel, Moderna CEO (Michael Brochstein/Sipa USA/Sipa via AP Images)
August 1, 2024 02:27 PM EDT
Pharma
Marketing

RSV mar­ket pres­sure leads to slow­er launch for Mod­er­na's vac­cine

Nicole DeFeudis

Editor

The RSV mar­ket is turn­ing out to be tougher than Mod­er­na hoped.

The com­pa­ny’s mResvia is the third RSV vac­cine to en­ter a mar­ket dom­i­nat­ed …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Mer­ck’s long-await­ed obe­si­ty move is an oral GLP-1 from Chi­na

Ma­jor PBM re­forms fea­ture in Con­gress' year-end spend­ing bill

What Trump’s FTC picks mean for bio­phar­ma deal­mak­ing and PBMs

Up­dat­ed: Ver­tex’s non-opi­oid pill dis­ap­points in mid-stage chron­ic pain study

A service from the Financial Times